Strumento inattivo

Altre lingue Pluristem Therapeutics Inc. Nasdaq

Azioni

US72940R1023

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Pluri Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	09/05
Pluri Inc. Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment	02/05
Pluri Inc. Announces Appointments to Its Scientific Advisory Board	02/05
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment	02/05
Pluri : 2023 Annual Report	01/05
Pluri : NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held On June 25, 2024	01/05
Pluri : DX Group opens first regional depot in the Republic of Ireland	26/04
Pluri : Material Event - Form 8-K	17/04
Sector Update: Health Care Stocks Decline Late Afternoon	08/04
Sector Update: Health Care	08/04
Pluri Receives US Patent for Immune Cell Expansion	08/04
Pluri Inc. Unveils A Novel Method for Expansion of Immune Cells Using Proprietary Technology	08/04
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method	08/04
Pluri : Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences	28/03
Pluri Inc. Announces 1-for-8 Reverse Share Split	27/03
Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report	21/03
Pluri : Announced its participation in upcoming conferences,details	19/03
Engage with Pluri's Talent: Exciting Conference Appearances Ahead	19/03
Pluri : Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturingor Announcement	14/03
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing	14/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Pluristem Therapeutics Inc. Nasdaq

Azioni

US72940R1023

Altre lingue

Filtri